The predictive significance of chromobox family members in prostate cancer in humans

Author:

Xu Xiaoting1,Lai Cong1,Luo Jiawen1,Shi Juanyi1,Guo Kaixuan1,Hu Jintao1,Mulati Yelisudan1,Xiao Yunfei1,Kong Degeng1,Liu Cheng1,Huang Jingang2,Xu Kewei1

Affiliation:

1. Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

2. Medical Research Center, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital

Abstract

Abstract Purpose The Chromobox (CBX) family proteins are crucial elements of the epigenetic regulatory machinery and play a significant role in the development and advancement of cancer. Nevertheless, there is limited understanding regarding the role of CBXs in development or progression of prostate cancer (PCa). Our objective is to develop a unique prognostic model associated with CBXs to improve the accuracy of predicting outcomes of patients with PCa. Methods Transcriptome sequencing and clinical data for PCa were obtained from the Cancer Genome Atlas and Gene Expression Omnibus databases. The data was then analyzed to identify differential expression, assess prognostic value, determine gene pathway enrichment, and evaluate immune cell infiltration. COX regression analysis was utilized to identify the independent prognostic factors that impact disease-free survival (DFS) in PCa, and subsequently, a nomogram was created. In vitro proliferation, migration and invasion assay were conducted to examine the function of CBX2 in PCa. Results CBX2, CBX3, CBX4, and CBX8 were upregulated, whereas CBX6 and CBX7 were downregulated in PCa tumor tissues. The expression level of these genes differs depending on the cancer's stage and grade. A negative outcome is associated with patients who have elevated levels of CBX1, CBX2, CBX3, CBX4 and CBX8 expression. An independent prognostic factors for PCa were the expression level of CBX2 and T stage, as well as Gleason score, as determined by Cox regression analysis. Additionally, a nomogram was created. The infiltration level of various immune cells is associated with the expression level of CBX2. In vitro studies have shown that the knockdown of CBX2 can greatly impede the growth, migration and invasion of PCa cells. Conclusion CBX2 is involved in the development and advancement of PCa, suggesting its potential as a reliable prognostic indicator for PCa patients.

Publisher

Research Square Platform LLC

Reference30 articles.

1. H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, CA Cancer J Clin. 71, 209–249 (2021). 10.3322/caac.21660

2. R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA Cancer J Clin. 72, 7–33 (2022). 10.3322/caac.21708

3. S. Gillessen, A. Bossi, I.D. Davis, J. de Bono, K. Fizazi, N.D. James, N. Mottet, N. Shore, E. Small, M. Smith, C. Sweeney, B. Tombal, E.S. Antonarakis, A.M. Aparicio, A.J. Armstrong, G. Attard, T.M. Beer, H. Beltran, A. Bjartell, P. Blanchard, A. Briganti, R.G. Bristow, M. Bulbul, O. Caffo, D. Castellano, E. Castro, H.H. Cheng, K.N. Chi, S. Chowdhury, C.S. Clarke, N. Clarke, G. Daugaard, M. De Santis, I. Duran, R. Eeles, E. Efstathiou, J. Efstathiou, O. Ngozi Ekeke, C.P. Evans, S. Fanti, F.Y. Feng, V. Fonteyne, N. Fossati, M. Frydenberg, D. George, M. Gleave, G. Gravis, S. Halabi, D. Heinrich, K. Herrmann, C. Higano, M.S. Hofman, L.G. Horvath, M. Hussain, B.A. Jereczek-Fossa, R. Jones, R. Kanesvaran, P.L. Kellokumpu-Lehtinen, R.B. Khauli, L. Klotz, G. Kramer, R. Leibowitz, C.J. Logothetis, B.A. Mahal, F. Maluf, J. Mateo, D. Matheson, N. Mehra, A. Merseburger, A.K. Morgans, M.J. Morris, H. Mrabti, D. Mukherji, D.G. Murphy, V. Murthy, P.L. Nguyen, W.K. Oh, P. Ost, J.M. O'Sullivan, A.R. Padhani, C. Pezaro, D.M.C. Poon, C.C. Pritchard, D.M. Rabah, D. Rathkopf, R.E. Reiter, M.A. Rubin, C.J. Ryan, F. Saad, J. Pablo, O.A. Sade, H.I. Sartor, N. Scher, I. Sharifi, H. Skoneczna, D.E. Soule, S. Spratt, C.N. Srinivas, T. Sternberg, H. Steuber, M.R. Suzuki, M.E. Sydes, D. Taplin, L. Tilki, F. Turkeri, H. Turco, H. Uemura, Y. Uemura, C.L. Urun, I. van Vale, Eur. Urol. 83, 267–293 (2023). Oort, N. Vapiwala, J. Walz, K. Yamoah, D. Ye, E.Y. Yu, A. Zapatero, T. Zilli and A. Omlin. 10.1016/j.eururo.2022.11.002

4. N.I. Simon, C. Parker, T.A. Hope, C.J. Paller, Am. Soc. Clin. Oncol. Educ. Book. 42, 1–8 (2022). 10.1200/EDBK_351033

5. S. Goel, V. Bhatia, T. Biswas, B. Ateeq, Semin Cancer Biol. 83, 136–151 (2022). 10.1016/j.semcancer.2021.01.009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3